Lipidation & Stapled Peptides: Enhancing Stability and Pharmacokinetics

The potential of peptide therapeutics is high because the targeting is highly specific, toxicity is low, and also the ability to affect complex biological determinants. These things are, however, hampered by issues like low stability, faster corrosion, low bioavailability, and low cell permeability, which limit their effectiveness in clinical conditions. This is why lipidation and peptide stapling approaches to balancing, which are highlighted in this review, are collaborators in challenging these questions. Lipidation is a covalent bonding of fatty acids or hydrophobic components, which increases the pharmacokinetics through better binding to albumin and enhancing half-life and through greater membrane interaction. Stapling also fixes α-helical structures with hydrocarbon or alternative linkers to improve resistance to proteolysis, structural stability, and intracellular transport. The sum of these changes results in a dual functionality peptide with an abnormally increased stability, bioavailability, and therapeutic effect. Other major case studies are antiviral agents targeted at SARS-CoV-2, antimicrobial peptides that include SLP-51, and stapled degraders targeting protein-protein interactions that are oncogenic. The balanced design frameworks, strategic placement of changes, linker techniques, and useful computational tools such as StaPep and Length LogD are also discussed in the review. Although issues of immunogenicity, scalability in manufacturing, and non-invasive delivery still remain, advances in peptide engineering and AI-inspired designing are also assisting in the future of dual-modified therapeutics. The combination of lipidation and stapling is a revolutionary technology that can revolutionize the development of peptide drugs in infectious diseases, cancer, and metabolic diseases.